Company profile
Revive Therapeutics Ltd.
OTC: RVVTF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Toronto, ONReports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH 9DQ —GM —SS 35
v0.1 · 35/100 weight · pillars only
↑ disclosure history, listing tenure · ↓ return on assets, Altman-Z
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$7.9M
Employees
3
as of 2026-08-22
Market cap
$7.8M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$00 CAD2025
Net income-$7.9M-11.0M CAD2025
Operating income-$1.2M-1.6M CAD2025
Total assets$150.3k205.0k CAD2025
Liabilities$2.7M3.7M CAD2025
Equity-$2.5M-3.5M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Revive Therapeutics Ltd.’s revenue?
Revive Therapeutics Ltd. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Lunai Bioworks Inc.20DGT Biopharma, Inc.32DPreveCeutical Medical Inc.——Unidoc Health Corp.——Vynleads, Inc.20DModular Medical, Inc.34DKey facts
CEOMichael Frank
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersToronto, ON
ExchangeOTC: RVVTF
Employees3
IPO date2015-12-02
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.